Molecular Immunology Laboratory (MIU)

The Molecular Immunology Laboratory strives to improve our understanding of the immune response in cancer and how it can be manipulated to the benefit of the patients. It investigates lymphocyte activities in several clinical conditions: 

• First, by studying the organization and cellular state of CD4+ T cells and germinal center B cells infiltrating the breast cancer microenvironment. This work involves both prospective studies designed to understand the functionality and subpopulations of tumor infiltrating lymphocytes present as well as their organization in peritumoral tertiary lymphoid structures, and retrospective studies that seek to apply these findings in the establishment of an immunological grade for breast cancer.
• Second, by identifying and characterizing specific changes in gene expression associated with clinical progression during the transition from pre-malignant disease to full-blown malignancy in patients with hypereosinophilic syndrome that develop T cell leukemia/lymphoma.
• Third, by analyzing specific changes in lymphocyte gene expression, with a focus on transcription factors regulating their normal activities, which are aberrantly regulated in human cancer. Our ultimate goal in the fight against cancer is to further understand how we can harness the power and the specificity of the immune response through its revitalization in the hostile tumor microenvironment to produce effective and sustained anti-tumor immunity.